Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Treasury Shares: 2021-2025

Historic Treasury Shares for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $330,092.

  • Krystal Biotech's Treasury Shares rose 6.64% to $330,092 in Q3 2025 from the same period last year, while for Sep 2025 it was $330,092, marking a year-over-year increase of 6.64%. This contributed to the annual value of $308,096 for FY2024, which is 91.48% up from last year.
  • As of Q3 2025, Krystal Biotech's Treasury Shares stood at $330,092, which was down 2.59% from $338,878 recorded in Q2 2025.
  • Krystal Biotech's 5-year Treasury Shares high stood at $348,757 for Q1 2025, and its period low was $66,600 during Q2 2022.
  • Over the past 3 years, Krystal Biotech's median Treasury Shares value was $309,553 (recorded in 2024), while the average stood at $269,528.
  • As far as peak fluctuations go, Krystal Biotech's Treasury Shares tumbled by 32.59% in 2022, and later skyrocketed by 159.31% in 2023.
  • Krystal Biotech's Treasury Shares (Quarterly) stood at $98,800 in 2021, then tumbled by 32.59% to $66,600 in 2022, then skyrocketed by 141.59% to $160,900 in 2023, then soared by 91.48% to $308,096 in 2024, then grew by 6.64% to $330,092 in 2025.
  • Its Treasury Shares stands at $330,092 for Q3 2025, versus $338,878 for Q2 2025 and $348,757 for Q1 2025.